ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Account Payables
Amounts the company owes suppliers for goods and services received.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 43.9% from a year ago
Account payables stood at $2.9M at the end of Q1 FY2026, down 43.9% from a year earlier and down 24.3% from the prior quarter. Over 3 fiscal years it compounded at +42.6% a year.
Context
- Account payables amounted to 0.7% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -43.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 3.82M USD
- Year-over-year change
- +147.0%
- 4-year CAGR
- +19.3%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.82M | +147.0% |
| FY2024 | 2024-12-31 | 1.55M | +64.0% |
| FY2023 | 2023-12-31 | 944K | -28.5% |
| FY2022 | 2022-12-31 | 1.32M | -30.0% |
| FY2021 | 2021-12-31 | 1.89M | — |
Account Payables vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's Mar 2026 account payables of $2.9M is the 10th highest of the 11 companies compared; the peer median is $4.7M.
- Its year-over-year change of -43.9% is the 10th highest of 11, against a peer median of +44.6%.
- Account payables amounts to 0.7% of total assets for ORIC, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $12.09M | -46.1% | +64.3% | 1.6% | |
| Mar 2026 | $10.84M | +7.9% | +56.2% | 2.3% | |
| Mar 2026 | $9.6M | +33.4% | +36.4% | 4.2% | |
| Mar 2026 | $8.73M | +100.0% | +24.2% | 2.5% | |
| Mar 2026 | $4.7M | +259.1% | +8.0% | 1.9% | |
| Mar 2026 | $4.7M | +56.9% | +29.2% | 18.5% | |
| Mar 2026 | $4.29M | -35.2% | -0.8% | 2.0% | |
| Mar 2026 | $3.64M | +45.7% | +1.0% | 0.9% | |
| Mar 2026 | $3.38M | +43.6% | +32.0% | 0.3% | |
| Mar 2026 | $2.9M | -43.9% | +42.6% | 0.7% | |
| Sep 2026 | $2.73M | +91.0% | -14.4% | 0.3% | |
| Peer median (excluding ORIC) | $4.7M | +44.6% | +26.7% | 1.9% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 226.01M | 66.84M | 23.38M | 59.41M | 45.67M |
| Short-term Investments | 10.97M | 139.43M | 184.8M | 196.55M | 235.82M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.19M | 4.41M | 6.29M | 6.98M |
| Total Current Assets | 240.52M | 210.46M | 212.6M | 262.25M | 288.47M |
| Property, Plant & Equipment (Net) | 2.41M | 14.25M | 12.01M | 2.92M | 9.07M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 43.39M | 22.42M | 27.34M | 0 | 111.25M |
| Tax Assets | 0 | 3.18M | 2.68M | 0 | 2.11M |
| Other Non-current Assets | 12.32M | 49K | 61K | 8.97M | 98K |
| Total Non-current Assets | 58.12M | 39.9M | 42.09M | 11.89M | 122.54M |
| Total Assets | 298.64M | 250.36M | 254.69M | 274.14M | 411M |
| Account Payables | 1.89M | 1.32M | 944K | 1.55M | 3.82M |
| Short-term Debt | 0 | 2.66M | 2.75M | 0 | 3.33M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.8M | 6.09M | 10.23M | 7.65M | 13.26M |
| Total Current Liabilities | 15.15M | 15.39M | 20.46M | 24.85M | 20.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 4.11M |
| Deferred Tax Liabilities | 0 | 3.18M | 2.68M | 0 | 2.11M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 10.52M | 0 | 0 | 6.17M | (4.11M) |
| Total Non-current Liabilities | 10.52M | 12.62M | 10.14M | 6.17M | 6.22M |
| Total Liabilities | 25.67M | 28.01M | 30.6M | 31.02M | 26.64M |
| Common Stock | 4K | 5K | 6K | 7K | 11K |
| Retained Earnings | (245.11M) | (334.23M) | (434.93M) | (562.77M) | (692.24M) |
| Accumulated OCI | (103K) | (1.29M) | 258K | 379K | 786K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 272.98M | 222.35M | 224.09M | 243.12M | 384.36M |
| Total Debt | 1.93M | 12.1M | 10.21M | 3.18M | 11.55M |
| Net Debt | (224.08M) | (54.74M) | (13.17M) | (56.22M) | (34.12M) |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.